Sarepta Will Challenge Expected No From EMA On Exondys 51

 
• By Sten Stovall

Sarepta is expecting the European Medicines Agency to recommend against EU approval of its Duchenne muscular dystrophy treatment eteplirsen. Persuading the agency to change its mind during the appeal will be an uphill task for the company.

Question mark
Sarepta’s DMD Drug Eteplirsen Has Been Rebuffed by European Regulators • Source: Shutterstock

More from Product Reviews

More from Pink Sheet